Competitors

Although there are a number of vaccines available for influenza it is widely recognised there is a desperate need for new ones, see WHO report here https://www.who.int/immunization/research/meetings_workshops/Universal_Influenza_VaccineRD_Sept2014.pdf and CDC site here https://www.cdc.gov/flu/
And in particular better vaccines are needed for more vulnerable groups, see link here https://www.cdc.gov/flu/about/disease/high_risk.htm

There is now increasing interest and growing evidence to support respiratory routes of vaccination. For example, ongoing Phase 1 clinical trials are looking at the efficacy of the when delivered via the inhalational route. However, our technology has the advantage of low-dose vaccination which is inherently more boostable, more cost-effective, quicker to manufacture therefore more suitable for the logistical challenges of the developing world and less likely to induce unwanted side-effects. Our approach provides cross protection against related strains and potentially many advantages over other potentially universal flu vaccines in development, see WHO link above.

Our vaccines are not capable of replication and are delivered to the lungs therefore they do not adversely affect immunity to bacteria in the lungs and are likely to be more effective with better cross protection.

There is now increasing interest and growing evidence to support respiratory routes of vaccination. For example, ongoing Phase 1 clinical trials are looking at the efficacy of the Oxford/Astra-Zeneca SARS-CoV-2 vaccine when delivered via the inhalational route. However, our technology has the advantage of low-dose vaccination which is inherently more boostable, more cost-effective, quicker to manufacture therefore more suitable for the logistical challenges of the developing world and less likely to induce unwanted side-effects. Our approach provides cross protection against related strains and potentially many advantages over other potentially universal flu vaccines in development, see WHO link above.

Our vaccines are not capable ofreplication and are delivered to the lungs therefore they do not adversely affect immunity to bacteria in the lungs and are likely to be more effective with better cross protection.